Entering text into the input field will update the search result below

Trevena: Taking A Systematic Approach With A Speculative Investment

May 05, 2021 10:43 PM ETTrevena, Inc. (TRVN) Stock7 Comments


  • Trevena has been on my watch list for a few years, but my buy conditions were never aligned. Now, I am looking to start a small position in TRVN.
  • The company's flagship product, OLINVYK, was launched back in January of this year. I don't expect the company to report impressive numbers considering the pandemic's impact on elective surgeries.
  • Trevena has a strong list of upcoming catalysts that should inject some momentum into the ticker until OLINVYK gets some grip in the market.
  • I plan on having a systematic approach to accumulating sizeable TRVN position over the remainder of 2021. I discuss my system and plans for TRVN.
Neuron system disease
Photo by koto_feja/E+ via Getty Images

Trevena, Inc. (NASDAQ:TRVN) has been on my watch list for a couple of years, but the conditions have never fit my liking for me to click the buy button. Now, I am considering starting a speculative investment ahead of some key catalysts

This article was written by

Biologics profile picture

Biologics is a full-time healthcare investor who developed a passion for biotech and life saving therapies after working in the medical field for years. His trade focus is around innovative companies developing breakthrough therapies and/or pharmaceuticals with catalysts for potential acquisitions.

He is the leader of the investing group Compounding Healthcare. Features of the group include: Several model healthcare portfolios, a weekly newsletter, a daily watchlist, and chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in TRVN over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (7)

Nice write-up. As following AcelRx (ACRX), their DSUVIA is sublingual, requires no IVs, no supplies, etc., also following, and ACRX has now 5 Phase 4 studies underway...
"The standard of care for perioperative opioid administration has not been disrupted for over 100 years."
- No Cognitive Impairment.
- No Respiratory Depression.
- 1 DSUVIA works on 100 pound patient or 300 pound patient, no dose adjustment.
- DSUVIA reduced time in the PACU.
- DSUVIA significant cost savings in the PACU.
- DSUVIA is Good Opioid Stewardship.
"Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit Following Preoperative Administration of Sublingual Sufentanil in an Ambulatory Surgery Setting" by Christian Tvetenstrand, MD and Michael Wolff, MD, in the Journal of Clinical Anesthesia and Pain Management.
Pierre Rossouw profile picture
Great analysis. Could be a great one.
But I like to see some substantial record, steady progress and deliverables in the real world. We will wait & see. Thanks for the history so far.
dogfriend profile picture
Thanks for your well written article. There is much to like about Tervena.
Reyan profile picture
Good strategy. You could make a lot of money by shorting it too.
oblvion profile picture
Trevena should have stuck with the name OLICERIDINE
Well versed article, holder for over 9 months!!
Nice price for a FDA approved product under its belt. Holder for about 8 months now. Will pay the patient investor well down the road
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About TRVN

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on TRVN

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.